{"id":1051,"slug":"韩国宣传的-干细胞丰胸-svf-和普通自体脂肪丰胸有什么区别-可信吗","question":"韩国宣传的“干细胞丰胸”（SVF）和普通自体脂肪丰胸有什么区别？可信吗？","intent":"comparison","language":"zh","url":"https://worldwiki.io/q/韩国宣传的-干细胞丰胸-svf-和普通自体脂肪丰胸有什么区别-可信吗","entity":{"slug":"breast-fat-grafting","name":"Breast Fat Grafting","url":"https://worldwiki.io/entity/breast-fat-grafting"},"answer":{"short_answer":"从监管角度看两者并不相同：按美国FDA 2017年11月发布的指南，自体脂肪移植不需要上市前批准，而基质血管组分（SVF）类产品会受到更严格的审查；FDA另有面向消费者的干细胞疗法风险提醒。本条目引用的两项SVF隆胸研究由医疗机构关联作者发表，属于提供方关联证据，不能视作独立验证。韩国与中国对这类细胞操作如何归类，不在本条目来源范围内，须向机构索取书面说明。","detailed_answer":"<p><strong>概念上的差别</strong>：普通自体脂肪丰胸是取出脂肪、处理后回注；SVF方案则涉及对脂肪进行进一步处理以获得基质血管组分再一起注射。</p><p><strong>监管上的差别（美国口径）</strong>：在FDA于2017年11月发布指南后，<strong>自体脂肪移植不需要上市前批准，而SVF类产品会受到更严格的审查</strong>。<sup>[6]</sup>相关指南为《21 CFR 1271.15(b) 同一手术例外：关于例外范围的问答》，该例外适用于在同一次手术中取出并回植的组织。<sup>[7]</sup>FDA还发布过面向消费者的干细胞疗法风险提醒。<sup>[17]</sup></p><p><strong>证据的独立性</strong>：本条目收录的两项SVF隆胸研究由医疗机构关联作者发表<sup>[11][16]</sup>，属于提供方关联证据；关于细胞辅助脂肪移植（CAL）与PRP辅助脂肪移植的系统综述则为独立文献<sup>[13][14]</sup>，另有一篇关于自体SVF临床使用安全性的文献综述<sup>[15]</sup>。查阅时应区分谁做的研究。</p><p><strong>需要如实说明的是</strong>：韩国和中国对SVF、干细胞类操作的具体法规归类<strong>不在本条目所引用的来源中</strong>。若医疗机构宣传“干细胞丰胸”，应要求对方以书面形式说明：注射的究竟是什么（未培养的SVF、PRP还是培养扩增的细胞）、在哪个许可设施内处理、适用哪部法规和哪个批准编号，并索取可核查的文件。</p>","format":"paragraph","confidence":75,"verified_at":null,"updated_at":"2026-09-20 17:11:10"},"sources":[{"id":274,"title":"Safety and Regulation of Fat Grafting (Raj S, Abu-Ghname A, Davis MJ, Izaddoost SA, Winocour SJ; Semin Plast Surg 2020;34(1):59–64)","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7023970/","publisher":"Seminars in Plastic Surgery (Thieme) via PubMed Central","type":"journal","accessed_at":"2026-09-19 18:00:35"},{"id":132,"title":"Same Surgical Procedure Exception under 21 CFR 1271.15(b): Questions and Answers Regarding the Scope of the Exception","url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/same-surgical-procedure-exception-under-21-cfr-127115b-questions-and-answers-regarding-scope","publisher":"US Food and Drug Administration (CBER)","type":"government","accessed_at":"2026-09-18 18:00:56"},{"id":27,"title":"A Study on Breast Augmentation Using Fat Grafting With Stromal Vascular Fraction (Shin DJ, Ann Plast Surg 2023;90(4):380-384)","url":"https://pubmed.ncbi.nlm.nih.gov/36881737/","publisher":"Annals of Plastic Surgery","type":"academic","accessed_at":"2026-09-19 18:00:57"},{"id":23,"title":"Cell-Assisted Lipotransfer: A Systematic Review of its Efficacy","url":"https://pubmed.ncbi.nlm.nih.gov/37608190/","publisher":"Aesthetic Plastic Surgery (2024)","type":"academic","accessed_at":"2026-09-19 18:01:02"},{"id":24,"title":"Comparison of the Efficacy and Safety of Cell-Assisted Lipotransfer and Platelet-Rich Plasma Assisted Lipotransfer","url":"https://pubmed.ncbi.nlm.nih.gov/33845642/","publisher":"Cell Transplantation (2021)","type":"academic","accessed_at":"2026-09-19 18:01:01"},{"id":20,"title":"Safety profile of autologous adipose-derived stromal vascular fraction in clinical use: an exhaustive literature review","url":"https://pubmed.ncbi.nlm.nih.gov/41618435/","publisher":"Stem Cell Research & Therapy (2026)","type":"academic","accessed_at":"2026-09-19 18:01:00"},{"id":28,"title":"Breast Augmentation by Fat Transplantation With Adipose-Derived Stem/Stromal Cells (Shin DJ, Aesthet Surg J Open Forum 2020)","url":"https://pubmed.ncbi.nlm.nih.gov/33791627/","publisher":"Aesthetic Surgery Journal Open Forum","type":"academic","accessed_at":"2026-09-19 18:00:58"},{"id":2,"title":"FDA Warns About Stem Cell Therapies","url":"https://www.fda.gov/consumers/consumer-updates/fda-warns-about-stem-cell-therapies","publisher":"U.S. Food and Drug Administration","type":"government","accessed_at":"2026-09-15 01:35:59"}],"published_at":"2026-09-20 08:11:10"}